VAXCYTE, INC. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax
VAXCYTE, INC. (PCVX) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax of -$4.12 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax · last filed 2026-08-05
- VAXCYTE, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2026-06-30 was -$4.12M, a 532.77% decline year-over-year.
- VAXCYTE, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2026-03-31 was -$8.73M, a 288.41% decline year-over-year.
- VAXCYTE, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2025-12-31 was $846.00K.
- VAXCYTE, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2025-09-30 was $3.03M, a 65.13% decline year-over-year.
- VAXCYTE, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2025 was $9.46M.
- VAXCYTE, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2024 was -$4.40M, a 917.47% decline from fiscal 2023.
- VAXCYTE, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2023 was $538.00K.
- VAXCYTE, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2022 was -$120.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.12M 10-Q · filed 2026-08-05 | -$12.85M 10-Q · filed 2026-08-05 | -$12.01M derived: sum of 3 quarters · filed 2026-08-05 | -$8.97M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$8.73M 10-Q · filed 2026-05-06 | -$7.88M derived: sum of 2 quarters · filed 2026-05-06 | -$4.85M derived: sum of 3 quarters · filed 2026-05-06 | -$3.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $846.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.88M derived: sum of 2 quarters · filed 2026-02-24 | $4.83M derived: sum of 3 quarters · filed 2026-08-05 | $9.46M 10-K · filed 2026-02-24 |
| 2025-09-30 | $3.03M 10-Q · filed 2025-11-04 | $3.98M derived: sum of 2 quarters · filed 2026-08-05 | $8.62M 10-Q · filed 2025-11-04 | -$2.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $952.00K 10-Q · filed 2026-08-05 | $5.59M 10-Q · filed 2026-08-05 | -$5.06M derived: sum of 3 quarters · filed 2026-08-05 | $3.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $4.63M 10-Q · filed 2026-05-06 | -$6.01M derived: sum of 2 quarters · filed 2026-05-06 | $2.68M derived: sum of 3 quarters · filed 2026-05-06 | $2.23M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$10.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$1.95M derived: sum of 2 quarters · filed 2026-02-24 | -$2.40M derived: sum of 3 quarters · filed 2026-02-24 | -$4.40M 10-K · filed 2026-02-24 |
| 2024-09-30 | $8.69M 10-Q · filed 2025-11-04 | $8.25M derived: sum of 2 quarters · filed 2025-11-04 | $6.25M 10-Q · filed 2025-11-04 | $8.71M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$445.00K 10-Q · filed 2025-08-06 | -$2.44M 10-Q · filed 2025-08-06 | $23.00K derived: sum of 3 quarters · filed 2026-02-24 | $254.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$2.00M 10-Q · filed 2025-05-07 | $468.00K derived: sum of 2 quarters · filed 2026-02-24 | $699.00K derived: sum of 3 quarters · filed 2026-02-24 | -$1.87M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $2.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.70M derived: sum of 2 quarters · filed 2026-02-24 | $130.00K derived: sum of 3 quarters · filed 2026-02-24 | $538.00K 10-K · filed 2026-02-24 |
| 2023-09-30 | $231.00K 10-Q · filed 2024-11-05 | -$2.34M derived: sum of 2 quarters · filed 2024-11-05 | -$1.93M 10-Q · filed 2024-11-05 | -$1.63M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$2.57M 10-Q · filed 2024-08-06 | -$2.16M 10-Q · filed 2024-08-06 | -$1.86M derived: sum of 3 quarters · filed 2025-02-25 | -$1.62M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $408.00K 10-Q · filed 2024-05-08 | $704.00K derived: sum of 2 quarters · filed 2025-02-25 | $951.00K derived: sum of 3 quarters · filed 2025-02-25 | $880.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $296.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $543.00K derived: sum of 2 quarters · filed 2025-02-25 | $472.00K derived: sum of 3 quarters · filed 2025-02-25 | -$120.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | $247.00K 10-Q · filed 2023-11-06 | $176.00K derived: sum of 2 quarters · filed 2023-11-06 | -$416.00K 10-Q · filed 2023-11-06 | -$645.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$71.00K 10-Q · filed 2023-08-08 | -$663.00K 10-Q · filed 2023-08-08 | -$892.00K derived: sum of 3 quarters · filed 2024-02-27 | -$896.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$592.00K 10-Q · filed 2023-05-08 | -$821.00K derived: sum of 2 quarters · filed 2024-02-27 | -$825.00K derived: sum of 3 quarters · filed 2024-02-27 | -$786.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$229.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$233.00K derived: sum of 2 quarters · filed 2024-02-27 | -$194.00K derived: sum of 3 quarters · filed 2024-02-27 | -$241.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | -$4.00K 10-Q · filed 2022-11-07 | $35.00K derived: sum of 2 quarters · filed 2022-11-07 | -$12.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $39.00K 10-Q · filed 2022-08-08 | -$8.00K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | -$47.00K 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |